Back to top
more

Lineage Cell Therapeutics (LCTX)

(Delayed Data from AMEX)

$1.14 USD

1.14
313,327

+0.03 (2.70%)

Updated Apr 26, 2024 04:00 PM ET

After-Market: $1.13 -0.01 (-0.88%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value F Growth B Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 30% (76 out of 252)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Brokerage Reports

Research for LCTX

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

 

0 items in cart

Lineage Cell Therapeutics, Inc. [LCTX]

Reports for Purchase

Showing records 81 - 97 ( 97 total )

Company: Lineage Cell Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 81

05/07/2020

Daily Note

Pages: 4

Busy Bees at Lineage Cell; VAC2 Option Exercised From CRUK Based on Immunogenicity Data

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 10.00

Research Provided by a Third Party

Company: Lineage Cell Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 82

05/06/2020

Company Report

Pages: 7

ARVO OpRegen Update Keep Things Nicely on Track

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 25.00

Research Provided by a Third Party

Company: Lineage Cell Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 83

05/05/2020

Company Report

Pages: 7

Straight to the Dendritic Cell Workhorse for COVID-19; Approach Makes Sense to Us

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 25.00

Research Provided by a Third Party

Company: Lineage Cell Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 84

05/05/2020

Company Report

Pages: 9

BUY: SARS-CoV-2 Vaccine - Maybe with CIRM

Provider: DAWSON JAMES SECURITIES, INC.

Analyst: KOLBERT J

Price: 25.00

Research Provided by a Third Party

Company: Lineage Cell Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 85

03/13/2020

Company Report

Pages: 7

2019 Results; Marching Towards Key Updates Through 2020 Beginning With Dry-AMD in Early May

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 25.00

Research Provided by a Third Party

Company: Lineage Cell Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 86

02/11/2020

Company Report

Pages: 9

Is the Market Seeing the Potential in AMD?

Provider: DAWSON JAMES SECURITIES, INC.

Analyst: KOLBERT J

Price: 25.00

Research Provided by a Third Party

Company: Lineage Cell Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 87

02/06/2020

Company Report

Pages: 9

All Signs Suggest Positive Progress in AMD

Provider: DAWSON JAMES SECURITIES, INC.

Analyst: KOLBERT J

Price: 25.00

Research Provided by a Third Party

Company: Lineage Cell Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 88

02/06/2020

Daily Note

Pages: 4

Checking off Important Boxes for OpRegen Program; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 10.00

Research Provided by a Third Party

Company: Lineage Cell Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 89

01/09/2020

Company Report

Pages: 9

Good Data Continues to be Visualized

Provider: DAWSON JAMES SECURITIES, INC.

Analyst: KOLBERT J

Price: 25.00

Research Provided by a Third Party

Company: Lineage Cell Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 90

01/03/2020

Company Report

Pages: 6

Starting 2020 With Positive Updates and Cash Infusion

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 25.00

Research Provided by a Third Party

Company: Lineage Cell Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 91

11/18/2019

Company Report

Pages: 8

KOLs Add Fuel to Our Lineage Investment Case

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 25.00

Research Provided by a Third Party

Company: Lineage Cell Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 92

11/13/2019

Company Report

Pages: 7

3Q19 Results; Continued Eyes on OpRegen Plus Pipeline Visibility in 2020; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 25.00

Research Provided by a Third Party

Company: Lineage Cell Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 93

10/15/2019

Company Report

Pages: 6

Positive OpRegen Clinical Update and Durability Case Continues to Build; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 25.00

Research Provided by a Third Party

Company: Lineage Cell Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 94

10/15/2019

Company Report

Pages: 9

Positive Update from AAO

Provider: DAWSON JAMES SECURITIES, INC.

Analyst: KOLBERT J

Price: 25.00

Research Provided by a Third Party

Company: Lineage Cell Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 95

09/19/2019

Company Report

Pages: 7

Renevia Awarded CE Mark in E.U.; Important Validation for Rebranded Lineage

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 25.00

Research Provided by a Third Party

Company: Lineage Cell Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 96

09/19/2019

Company Report

Pages: 9

Proof of Concept - Check That Box

Provider: DAWSON JAMES SECURITIES, INC.

Analyst: KOLBERT J

Price: 25.00

Research Provided by a Third Party

Company: Lineage Cell Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 97

08/12/2019

Company Report

Pages: 9

BioTime More Than Just a Name Change

Provider: DAWSON JAMES SECURITIES, INC.

Analyst: KOLBERT J

Price: 25.00

Research Provided by a Third Party